Based in Secaucus, New Jersey, Quest Diagnostics Incorporated (DGX), with a market capitalization of approximately $25.8 billion, is a leading provider of diagnostic information services. The company offers laboratory testing and health insights that help consumers, physicians and hospitals screen, prevent, diagnose and monitor diseases, while improving access to affordable and actionable healthcare information.
DGX is set to report its Q3 earnings on Thursday, October 22, 2026, before the market opens. Ahead of the release, analysts expect the company to report diluted EPS of $2.85, up 9.6% from $2.60 in the year-ago quarter. Quest Diagnostics has also exceeded Wall Street’s EPS estimates in each of the past four quarters, highlighting its consistent earnings performance.